published meta-analysis   sensitivity analysis   studies

budesonide in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalization or deathdetailed resultsPRINCIPLE, 2021 0.81 [0.58; 1.13] 0.81[0.58; 1.13]PRINCIPLE, 202110%1,660NAnot evaluable clinical improvementdetailed resultsPRINCIPLE, 2021 1.21 [1.08; 1.36] 1.21[1.08; 1.36]PRINCIPLE, 202110%1,779NAnot evaluable mechanical ventilationdetailed resultsPRINCIPLE, 2021 1.02 [0.45; 2.33] 1.02[0.45; 2.33]PRINCIPLE, 202110%1,503NAnot evaluable ICU admissiondetailed resultsPRINCIPLE, 2021 0.54 [0.24; 1.21] 0.54[0.24; 1.21]PRINCIPLE, 202110%1,491NAnot evaluable recoverydetailed resultsPRINCIPLE, 2021 1.21 [1.08; 1.36] 1.21[1.08; 1.36]PRINCIPLE, 202110%1,779NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-29 12:41 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 926 - roots T: 290